Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report)'s share price traded down 4.9% on Wednesday . The company traded as low as $0.77 and last traded at $0.82. 1,352,031 shares traded hands during mid-day trading, an increase of 116% from the average session volume of 626,560 shares. The stock had previously closed at $0.86.
Wall Street Analyst Weigh In
VRCA has been the subject of several analyst reports. HC Wainwright reissued a "neutral" rating on shares of Verrica Pharmaceuticals in a report on Tuesday, April 8th. Needham & Company LLC reissued a "hold" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, May 14th. Finally, Wall Street Zen raised shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $8.00.
Read Our Latest Stock Analysis on VRCA
Verrica Pharmaceuticals Trading Down 7.6%
The business's fifty day moving average price is $0.61 and its 200-day moving average price is $0.61. The company has a market capitalization of $74.60 million, a P/E ratio of -0.67 and a beta of 1.76.
Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company had revenue of $3.44 million during the quarter, compared to analysts' expectations of $2.53 million. As a group, equities research analysts forecast that Verrica Pharmaceuticals Inc. will post -1.46 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in VRCA. Geode Capital Management LLC grew its position in Verrica Pharmaceuticals by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 477,269 shares of the company's stock worth $334,000 after acquiring an additional 21,789 shares in the last quarter. Invesco Ltd. purchased a new stake in Verrica Pharmaceuticals during the fourth quarter valued at about $32,000. Renaissance Technologies LLC boosted its position in Verrica Pharmaceuticals by 57.7% during the fourth quarter. Renaissance Technologies LLC now owns 233,300 shares of the company's stock valued at $163,000 after buying an additional 85,336 shares during the period. Heights Capital Management Inc. purchased a new stake in Verrica Pharmaceuticals during the fourth quarter valued at about $246,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals during the fourth quarter valued at about $1,811,000. 42.45% of the stock is currently owned by hedge funds and other institutional investors.
About Verrica Pharmaceuticals
(
Get Free Report)
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Featured Articles
Before you consider Verrica Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.
While Verrica Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.